Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2021

View Archived Issues

Immune response research shows GM-CSF plays role in COVID-19 severity

Many elite controllers at HIV's ground zero

Targeting membrane protein starves pancreatic tumors

Henlius initiates dosing in phase II/III study of HLX-10 plus bevacizumab in first-line mCRC

Chinese researchers disclose SCN10A blockers

Hunan Warrant Pharmaceuticals patents Bcr-Abl1 and/or BTK inhibitors

Inflazome synthesizes new NLRP3 inflammasome inhibitors

Galapagos presents TYK2 inhibitors

Successful completion of IND-enabling rodent toxicology studies with R-107

The Feinstein Institute for Medical Research divulges tetranectin-targeting antibodies

GSK-3640254 demonstrates safety and dose-antiviral response relationship in phase IIa trial

ALG-097111: targeting 3CLpro for treating SARS-CoV-2

E-2027 improves cognitive function in mouse model of AD

Inhibrx identifies MTD of INBRX-105 in first-in-human study in solid tumors

I-SPY COVID trial drops apremilast for futility

DARPins as promising mutation-resistant antivirals for potential SARS-CoV-2 treatment

Tilt advances phase I trial of TILT-123 in metastatic melanoma

New phase II trial investigates Tedopi with Keytruda for recurrent ovarian cancer

Phase III trial of Libtayo in advanced cervical cancer stopped early for favorable OS data

Helixmith initiates phase II study of Engensis in ALS

Improved delivery observed for ABL-301 in mouse models of PD

IFN-mediated NAD depletion by upregulation of PARP9/10/14 sensitizes PDAC cells to NAMPT inhibitors

NSD3 drives oncogenesis in LUSC, but may sensitize these tumors to bromodomain inhibition

Boehringer Ingelheim ends phase II trial of BI-764198 for COVID-19-related ARDS

SiteOne initiates phase I study of ST-2427 in healthy volunteers

Rubius reports initial data from phase I/II study of RTX-240 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...